Elvinix secures exclusive license for type 1 diabetes peptide therapy
The company will advance a novel peptide intended to restore insulin production in patients with type 1 diabetes.
PR
By Priya Raman · Science Reporter
Sep 15 07:00 ETSource: Business Wire
The wire
- 01Elvinix announced an exclusive license to a novel peptide therapy for type 1 diabetes.
- 02Targets insulin production restoration, a different goal than glucose control alone.
- 03Preclinical and clinical milestones ahead were not specified in the release.
From the source
Read at news.google.comElvinix Secures Exclusive License to Advance Novel Peptide Therapy Aimed at Restoring Insulin Production in Type 1 Diabetes